What is Cobenfy (xanomeline/trospium) and how is it used for the treatment of schizophrenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Cobenfy?

Cobenfy (xanomeline/trospium chloride) is the first FDA-approved non-dopaminergic antipsychotic medication for treating schizophrenia in adults, combining a muscarinic M1/M4 receptor agonist (xanomeline) with a peripheral muscarinic antagonist (trospium) to provide efficacy while minimizing cholinergic side effects. 1

Mechanism of Action

Cobenfy represents a paradigm shift in schizophrenia treatment by targeting the cholinergic system rather than dopamine receptors. Xanomeline acts as a preferential agonist at M1 and M4 muscarinic acetylcholine receptors in the central nervous system, which mediates the antipsychotic effects. Trospium chloride, which does not cross the blood-brain barrier, blocks peripheral muscarinic receptors to reduce gastrointestinal and other cholinergic side effects that would otherwise occur from xanomeline's peripheral activity. 2, 3

FDA-Approved Indication

Cobenfy is indicated for the treatment of schizophrenia in adults. 1

Dosing and Administration

The recommended starting dose is 50 mg/20 mg (xanomeline/trospium) orally twice daily for at least 2 days, then increase to 100 mg/20 mg twice daily for at least 5 days. The dose may be further increased to 125 mg/30 mg twice daily based on tolerability and response. 1

Critical administration requirements:

  • Take at least 1 hour before meals or at least 2 hours after meals
  • Do not open capsules
  • Assess liver enzymes, bilirubin, and heart rate before starting treatment 1

For geriatric patients: Start at 50 mg/20 mg twice daily with slower titration; maximum dose is 100 mg/20 mg twice daily. 1

Clinical Efficacy

In Phase 3 trials (EMERGENT-1 and EMERGENT-2), Cobenfy demonstrated significant reductions in PANSS total scores compared to placebo, with Cohen's d effect sizes around 0.60. The medication showed reductions in positive symptoms approximately 1.5-2 times greater than placebo and negative symptoms 1.5-3.5 times greater than placebo. 4, 5

Long-term data from 52-week open-label studies showed that over 75% of participants achieved >30% improvement in PANSS total scores, with mean decreases of 33.3 points. 4

Safety Profile and Contraindications

Cobenfy is absolutely contraindicated in patients with:

  • Urinary retention
  • Moderate or severe hepatic impairment
  • Gastric retention
  • Untreated narrow-angle glaucoma
  • History of hypersensitivity to Cobenfy or trospium chloride 1

Most common adverse effects (≥5% and at least twice placebo rate):

  • Nausea, dyspepsia, constipation, vomiting (gastrointestinal effects are typically mild-to-moderate)
  • Hypertension and tachycardia
  • Abdominal pain and diarrhea
  • Dizziness
  • Gastroesophageal reflux disease 1

Critical advantage over traditional antipsychotics: Cobenfy does not cause weight gain, extrapyramidal symptoms, hyperprolactinemia, or metabolic syndrome because it does not block dopamine D2 receptors. 3, 6

Important Warnings

  • Urinary retention risk: Elderly patients and those with bladder outlet obstruction or benign prostatic hyperplasia are at increased risk 1
  • Hepatic monitoring: Assess liver enzymes and bilirubin before starting and as clinically indicated; discontinue if signs of substantial liver injury develop 1
  • Heart rate increases: Monitor heart rate at baseline and during treatment 1
  • CNS effects: May cause dizziness, confusion, hallucinations, and somnolence; advise patients not to drive until they know how the medication affects them 1
  • Not recommended: In patients with moderate-to-severe renal impairment or mild hepatic impairment 1

Place in Therapy Context

While the 2025 INTEGRATE guidelines 7 and 2020 APA guidelines 8 do not specifically mention Cobenfy (as it was approved in September 2024), the general principles of schizophrenia treatment emphasize shared decision-making based on side-effect profiles and patient preferences. Cobenfy offers a particularly valuable option for patients who cannot tolerate the metabolic or motor side effects of traditional dopamine-blocking antipsychotics. 5

Adherence Challenges

A critical caveat: Discontinuation rates in clinical trials were substantial (51-78% in long-term studies), with gastrointestinal side effects and voluntary withdrawal being major factors. 5 This suggests that while the medication is effective, careful patient selection, education about expected side effects, and close monitoring during the initial titration period are essential for success.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.